Novartis AG / Tourmaline Bio, Inc.

Atherosclerotic Cardiovascular Disease (ASCVD) - residual inflammatory risk (elevated hsCRP)

805K US cases/yr · $4.5B Estimated peak potential for IL-6/inflammation-targeted ASCVD therapy (analyst consensus range $3-6B) · ~40% Share of secondary-prevention ASCVD patients with residual inflammatory risk (hsCRP >=2 mg/L) despite optimal LDL control

Disease Overview

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death in the United States, encompassing coronary artery disease, stroke, and peripheral artery disease. Despite aggressive LDL-cholesterol lowering with statins, ezetimibe, and PCSK9 inhibitors, approximately 30-40% of secondary-prevention patients continue to suffer recurrent major adverse cardiovascular events (MACE). The CANTOS trial (canakinumab) and subsequent JUPITER, CIRT, and ZEUS studies established that residual inflammatory risk - marked by elevated high-sensitivity C-reactive protein (hsCRP >=2 mg/L) - is an independent driver of atherothrombotic events, mediated largely through IL-6 signaling downstream of the NLRP3 inflammasome. The CDC estimates approximately 20.5 million US adults have coronary artery disease, and roughly 805,000 Americans have a heart attack each year. Among post-MI and high-risk secondary-prevention patients, 30-50% have residual inflammation (hsCRP >=2 mg/L) despite LDL control, defining a large targetable subpopulation for anti-inflammatory therapy. Chronic kidney disease (CKD) with cardiovascular risk represents a high-priority adjacent indication, given pacibekitug's TRANQUILITY Phase 2 data in CKD.

Competitive Landscape

The residual-inflammation ASCVD field is defined by IL-6 pathway and NLRP3 inflammasome inhibition. Ziltivekimab (Novo Nordisk, anti-IL-6 mAb) is the most advanced competitor with Phase 3 ZEUS, ARTEMIS, and HERMES trials reading out 2025-2026 in ASCVD+CKD and post-MI settings. Novo's acquisition of Corvidia for $2.1B (2020) established this category. Canakinumab (Novartis' Ilaris, anti-IL-1-beta mAb) validated the inflammatory-risk hypothesis in CANTOS but was not pursued commercially in ASCVD due to infection signals. Additional entrants include ARCH Venture's ARCH-1 (anti-IL-6), Biogen/Denali small-molecule NLRP3 inhibitors, Olatec/Ventus/NodThera NLRP3 programs (dapansutrile), and low-dose colchicine (Agepha Pharma's Lodoco, FDA-approved 2023). Pacibekitug (formerly TOUR006) is a long-acting fully-human IgG1 anti-IL-6 ligand mAb dosed subcutaneously every 3-6 months, differentiated from ziltivekimab's monthly dosing. Positive TRANQUILITY Phase 2 data in CKD showed >90% hsCRP suppression, supporting a potential best-in-class tolerability and convenience profile for Novartis to compete against Novo's ziltivekimab franchise.